

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



和 鉑 醫 藥 控 股 有 限 公 司

HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 02142)

**VOLUNTARY ANNOUNCEMENT
BUSINESS UPDATE ON THE GRANT OF BREAKTHROUGH
THERAPY DESIGNATION TO BATOCLIMAB (HBM9161)
BY CHINA CENTER FOR DRUG EVALUATION**

This announcement is made by HBM Holdings Limited (the “**Company**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update.

The board of directors of the Company (the “**Board**”) is pleased to announce that China Center for Drug Evaluation (“**CDE**”) has granted Breakthrough Therapy designation to batoclimab (HBM9161), a fully human anti-FcRn monoclonal antibody (mAb), for the treatment of adult patients with Myasthenia Gravis (“**MG**”).

MG, mediated by pathogenic IgG, is a severely debilitating condition that manifests itself in the form of skeletal muscle contraction and weakness limiting movement and could even result in fatal respiratory failure. In China, an estimate of 250,000 patients suffer from this condition. Current therapies are limited due to inadequate efficacy, safety issues or limited availability.

Batoclimab (HBM9161), a fully human anti-FcRn mAb, blocks FcRn-IgG interactions, accelerates the degradation of autoantibodies and leads to the treatment of pathogenic IgG-mediated autoimmune diseases. Available evidence suggests that reduced levels of pathogenic IgG in patients with myasthenia gravis are associated with clinical benefit. Earlier studies demonstrated that batoclimab (HBM9161) is well tolerated and can rapidly reduce total IgG. These findings make batoclimab (HBM9161) the first anti-FcRn to demonstrate a sustained IgG reduction in both Chinese and Caucasian populations when administered via subcutaneous (SC) injection.

Cautionary statement: We cannot guarantee that we will be able to develop, or ultimately market, batoclimab (HBM9161) successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman

Hong Kong, January 28, 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Jingsong Wang, Dr. Mai-Jing Liao, and Dr. Atul Mukund Deshpande as executive Directors; Mr. Yu Min Qiu and Mr. Junfeng Wang as non-executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Ms. Weiwei Chen as independent non-executive Directors.